정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2291 | Recruiting | A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 | COVID-19 | Drug: Placebo Administration Biological: Vaccine Therapy |
Phase 1 | City of Hope Medical Center, National Cancer Institute (NCI) | OTHER | 129 | All | 18 Years ~ 55 Years | City of Hope Medical Center, Duarte, California, United States |
2290 | Recruiting | A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial | Covid19 | Biological: Vaccination once with Janssen vaccine (only priming) Biological: Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting). Biological: Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting). Biological: Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting). |
Not Applicable | Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | OTHER | 432 | All | 18 Years ~ 65 Years | AmsterdamUMC, Amsterdam, Netherlands UMCG, Groningen, Netherlands LUMC, Leiden, Netherlands Erasmus MC, Rotterdam, Netherlands |
2289 | Active, not recruiting | A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults | Corona Virus Infection | Biological: ARCT-021 single dose priming Biological: ARCT-021 two lower dose priming Biological: ARCT-021 two higher dose priming Biological: Placebo (two doses), priming Biological: Randomized booster Biological: Placebo booster |
Phase 2 | Arcturus Therapeutics, Inc. | INDUSTRY | 600 | All | 18 Years | Arcturus Investigational Site 103, Chandler, Arizona, United States Arcturus Investigational Site 107, Tucson, Arizona, United States Arcturus Investigational Site 112, San Diego, California, United States Arcturus Investigational Site 104, Melbourne, Florida, United States Arcturus Investigational Site 105, Orlando, Florida, United States Arcturus Investigational Site 106, Pinellas Park, Florida, United States Arcturus Investigational Site 109, The Villages, Florida, United States Arcturus Investigational Site 101, Peoria, Illinois, United States Arcturus Investigational Site 110, Rockville, Maryland, United States Arcturus Investigational Site 102, Anderson, South Carolina, United States Arcturus Investigational Site 111, Austin, Texas, United States Arcturus Investigational Site 108, Dallas, Texas, United States Arcturus Investigational Site 204, Singapore, Singapore Arcturus Investigational Site 201, Singapore, Singapore Arcturus Investigational Site 203, Singapore, Singapore |
2288 | Recruiting | A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults | Corona Virus Infection | Biological: ARCT-165 Biological: ARCT-154 Biological: ARCT-021 |
Phase 2 | Arcturus Therapeutics, Inc. | INDUSTRY | 72 | All | 21 Years ~ 80 Years | Arcturus Investigational Site 201, Kansas City, Missouri, United States Arcturus Investigational Site 101, Singapore, Singapore |
2287 | Recruiting | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults | Protection Against COVID-19 and Infections With SARS CoV 2 | Biological: BNT162a1 Biological: BNT162b1 Biological: BNT162b2 Biological: BNT162c2 |
Phase 2 | BioNTech SE | INDUSTRY | 476 | All | 18 Years ~ 85 Years | Contract Research Organization, Berlin, Germany Universitats Klinikum, Frankfurt am Main, Germany Universitats Klinikum, Heidelberg, Germany Contract Research Organization, Kiel, Germany Contract Research Organization, Mannheim, Germany |
2286 | Active, not recruiting | A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults | Protection Against COVID-19 | Biological: BNT162b3 | Phase 2 | BioNTech SE | INDUSTRY | 96 | All | 18 Years ~ 85 Years | Contract Research Organization, Berlin, Germany Contract Research Organization, Mannheim, Germany |
2285 | Recruiting | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects | SARS-CoV-2 Infection | Biological: BNT162b2s01 Biological: BNT162b2 |
Phase 2 | BioNTech SE | INDUSTRY | 549 | All | 18 Years | CRS Clinical Research Services Berlin GmbH, Berlin, Germany University Hospital Frankfurt, Infectiology, Frankfurt, Germany University Hospital Heidelberg, Clinical Pharmacology, Heidelberg, Germany CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany |